New ForeCYTE Breast Health Test uses simple, noninvasive fluid sample to
determine breast cancer risk
SEATTLE, Aug. 2, 2013 /PRNewswire/ -- Virtually all American women are aware
that the pink ribbon is the symbol of breast cancer awareness. Despite this
near-universal recognition, it is still a sad fact that plenty of women do not
truly appreciate the extent to which they are at risk for breast cancer.
Fresh evidence comes from a recent study by the Mayo Center Clinic for the
Science of Health Care Delivery. Researchers found that breast cancer patients
in rural areas of the U.S. are less likely than those in cities to receive
recommended radiation therapy after having a lumpectomy--a breast-sparing
surgery that removes only tumors and surrounding tissue. This is worrisome
because lack of follow-up radiation therapy could lead to recurrence and further
The study also found that rural women were less likely to have their
estrogen-receptor status tested and their tumor graded--two important parts of
the diagnostic work-up for breast cancer--and were also more likely to choose
mastectomy (complete removal of the breast) rather than lumpectomy.
An interesting new approach has been developed by Atossa Genetics, Inc. The
ForeCYTE Breast Health Test incorporates the use of an FDA-cleared, patented
device, similar to a breast pump in appearance, that collects nipple fluid for
testing in women between ages 18 and 73. The collected fluid can be used to
identify normal versus premalignant versus malignant cells. The procedure is
noninvasive, virtually painless for the patient, and takes about 10 minutes. If
necessary, precancerous changes can be addressed with lifestyle intervention or
Ultimately, precancerous changes may be treated locally with therapy, also being
developed by Atossa. The therapeutic system, which is in the research phase,
will provide drugs to be introduced into a "sick duct" and reverse early changes
before they become malignant. This technique avoids treating the entire patient
with powerful but toxic drugs, instead acknowledging that the problem lies with
a milk duct two inches long and the diameter of an angel hair pasta strand.
Women who might be at risk for breast cancer should ask their doctors if the
ForeCYTE test is right for them. For more information, please visit
Contact: Laura Radocaj, Dian Griesel Int'l. 212.825.3210
SOURCE Atossa Genetics, Inc.